Issuer: MIV Therapeutics Inc (OTCBB: MIVT)

Analyst Firm:  SISM Research

Ratings Action: REITERATION

Current Rating: Speculative Buy

Target Price Action: INCREASE
Target Price: $2.50 (+66.67% from $1.50)

Analyst Comments: The firm notes that since their June updated report, the stock has tripled in price but there is still considerable value to be unlocked. MIVT gained investors confidence based on very encouraging results from its latest animal trials which pave the way for human clinical trials scheduled to commence in early 2006. They also point out that MIVTapeutics also won the prestigious Frost & Sullivan 2005 Technology Innovation Award for Advanced Medical Coatings. MIVT's planed acquisition of Sahajanand Medical Technologies Inc. has not yet bee completed, but the firm believes it will be soon. SMT's state-of-the-art production technology and worldwide distribution, combined with MIVT's proprietary coating technology, will provide a powerful synergy that will make MIVT a major industry player in which MIVT become a major commercial provider in the rapidly growing market for both cardiac and other types of implantable medical devices, in the firm's opinion.

This rating information was reported by SISM Research.